Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18590729 | SELECTIVE REDUCTION OF ANTIBODIES | Non-Final OA | AbbVie Inc. |
| 17934996 | PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17775198 | IDENTIFICATION OF SPLICING-DERIVED ANTIGENS FOR TREATING CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17920461 | DUOCARMYCIN DERIVATIVE AND USE THEREOF | Final Rejection | TOHOKU UNIVERSITY |
| 17612280 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Final Rejection | Novartis AG |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | Final Rejection | MedImmune, LLC |
| 18328288 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES | Final Rejection | ImmunoGen, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy